Psychiatric Times
August 2005
Vol. XXII
Issue 9
Sponsored by CME LLC for 1.5 Category 1 credits.
Original release date 8/05. Approved for CME credit through 7/31/06.
Educational Objectives:
Upon completion of this educational activity, the reader will be familiar with:
- The epidemiology of obesity and the metabolic syndrome in patients with mental illness.
- The neurobiology and magnitude of metabolic effects associated with antipsychotics.
- Evaluating the differential risks associated with atypical antipsychotics.
- Implementing treatment strategies and medical monitoring to optimize outcomes while minimizing risks.
Who will benefit from reading this article?
Psychiatrists, primary care physicians, neurologists, nurse practitioners, psychiatric nurses and other mental health care professionals. Continuing medical education credit is available for most specialties. To determine if this article meets the CE requirements for your specialty, please contact your state licensing board.
Dr. Narasimhan is the director of the psychopharmacology program in the department of neuropsychiatry and behavioral sciences at the University of South Carolina School of Medicine and serves as consultant to the Department of Mental Health in Columbia, S.C. Dr. Narasimhan has received grant and research support from Bristol-Myers Squibb and Janssen Pharmaceutica Products, L.P. She has been a consultant for Abbott Laboratories and is a member of the speakers' bureau for Pfizer, Inc.
Dr. Gupta is chairperson of the department of psychiatry at Olean General Hospital in Olean, N.Y. He is clinical professor in the department of psychiatry at the University of Buffalo School of Medicine and Biomedical Sciences and the State University of New York Upstate Medical University. Dr. Gupta has received research grants from Abbott Laboratories; AstraZeneca Pharmaceuticals, L.P.; Eli Lilly and Company; Forest Laboratories, Inc.; GlaxoSmithKline; Johnson & Johnson; Neurochem; and Sanofi-Aventis. He has been a consultant for Eli Lilly; Forest and Shire US, Inc., and a member of the speakers' bureau for Eli Lilly, Forest, GlaxoSmithKline, Shire and Wyeth. He holds stock in Abbott Laboratories and Merck & Company.
